{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:12:09Z","timestamp":1776366729873,"version":"3.51.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:p>The objective of this study was to evaluate the utility of serum C-reactive protein (CRP) as biomarker for the early diagnosis of immune-related adverse events (irAEs) in melanoma patients treated with immune checkpoint inhibitors (ICIs) in the adjuvant setting, and its potential correlation with relapse-free survival (RFS). Prospectively collected data from 72 melanoma patients treated with adjuvant ICIs were pooled. CRP values at diagnosis of 10 irAEs were descriptively analysed. Correlations between RFS and the occurrence of irAEs, the grade of the irAE, the extent of CRP-elevation and the use of corticosteroids for irAE treatment were investigated. A total of 191 irAEs (grade 1\/2, <jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u2009182; grade 3\/4, <jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u20099) occurred in 64 patients [skin toxicity (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200970), fatigue (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200950), thyroiditis (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200912), musculoskeletal toxicity (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200911), sicca syndrome (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200910), other (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u200923), pneumonitis (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u20096), colitis (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u20094), hepatitis (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u20093) and hypophysitis (<jats:italic toggle=\"yes\">n<\/jats:italic>\u2009=\u20092)]. In pneumonitis and hypophysitis, the median CRP levels at diagnosis exceeded the upper limit of normal (ULN, 5\u2009mg\/L). After a median follow-up of 26.5\u2009months, 28 patients (39%) had been diagnosed with a melanoma relapse. Patients who experienced no irAE were at the highest risk for relapse (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.008). A trend was observed for patients diagnosed with an irAE that was associated with an elevated CRP (&gt;2xULN) to be at higher risk for relapse as compared to those diagnosed with an irAE and CRP &lt;ULN (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009=\u20090.054). CRP has potential as biomarker for the early detection of selected irAEs. Dynamic evaluation can guide irAE diagnosis, regression or relapse. The observed correlation between irAEs associated with an elevated CRP and risk for recurrence deserves further investigation.<\/jats:p>","DOI":"10.1097\/cmr.0000000000000748","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:03:17Z","timestamp":1622422997000},"page":"371-377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting"],"prefix":"10.1097","volume":"31","author":[{"given":"Justine","family":"Lauwyck","sequence":"first","affiliation":[{"name":"UZ Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Beckw\u00e9e","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Brussel, Brussels Health Campus, Jette, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno","family":"Santens","sequence":"additional","affiliation":[{"name":"Vrije Universiteit Brussel, Brussels Health Campus, Jette, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia Katharina","family":"Schwarze","sequence":"additional","affiliation":[{"name":"UZ Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Awada","sequence":"additional","affiliation":[{"name":"UZ Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Vandersleyen","sequence":"additional","affiliation":[{"name":"UZ Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[{"name":"UZ Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Neyns","sequence":"additional","affiliation":[{"name":"UZ Brussel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"R1-20250528","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma \u2013 an update.","volume":"9","author":"Gellrich","year":"2020","journal-title":"J Clin Med"},{"key":"R2-20250528","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CCO.0000000000000610","article-title":"Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting.","volume":"32","author":"Herrscher","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"R3-20250528","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma.","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"R4-20250528","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma.","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"key":"R5-20250528","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma.","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"R6-20250528","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma.","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"R7-20250528","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/ITT.S126227","article-title":"Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.","volume":"6","author":"Yoest","year":"2017","journal-title":"Immunotargets Ther"},{"key":"R8-20250528","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"R9-20250528","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"R10-20250528","doi-asserted-by":"crossref","first-page":"iv264","DOI":"10.1093\/annonc\/mdy162","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"R11-20250528","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"R12-20250528","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"R13-20250528","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"R14-20250528","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2019.12.031","article-title":"Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)\/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: a multicentre analysis of immune-related adverse events.","volume":"128","author":"Cortellini","year":"2020","journal-title":"Eur J Cancer"},{"key":"R15-20250528","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1111\/cas.13800","article-title":"Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab.","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"R16-20250528","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1002\/cncr.32966","article-title":"Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis.","volume":"126","author":"Tyan","year":"2020","journal-title":"Cancer"},{"key":"R17-20250528","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/annonc\/mdz224","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.","volume":"30","author":"Chaput","year":"2019","journal-title":"Ann Oncol"},{"key":"R18-20250528","doi-asserted-by":"crossref","first-page":"10391","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis.","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"R19-20250528","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jdermsci.2016.12.019","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity.","volume":"86","author":"Tanaka","year":"2017","journal-title":"J Dermatol Sci"},{"key":"R20-20250528","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma.","volume":"3","author":"Tarhini","year":"2015","journal-title":"J Immunother Cancer"},{"key":"R21-20250528","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy.","volume":"25","author":"Lim","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R22-20250528","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2017.12.008","article-title":"Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.","volume":"91","author":"Danlos","year":"2018","journal-title":"Eur J Cancer"},{"key":"R23-20250528","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI96798","article-title":"Early B cell changes predict autoimmunity following combination immune checkpoint blockade.","volume":"128","author":"Das","year":"2018","journal-title":"J Clin Invest"},{"key":"R24-20250528","doi-asserted-by":"crossref","first-page":"1722023","DOI":"10.1080\/2162402X.2020.1722023","article-title":"Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment.","volume":"9","author":"Kim","year":"2020","journal-title":"Oncoimmunology"},{"key":"R25-20250528","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","article-title":"C-reactive protein as an early marker of immune-related adverse events.","volume":"145","author":"Abolhassani","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"15_Suppl","key":"R26-20250528","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1200\/JCO.2019.37.15_suppl.9585","article-title":"A sequential dual cohort phase II clinical trial on adjuvant low-dose nivolumab with or without low-dose ipilimumab as adjuvant therapy following the resection of melanoma macrometastases (MM).","volume":"37","author":"Schwarze","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15_Suppl","key":"R27-20250528","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1200\/JCO.2019.37.15_suppl.100","article-title":"Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.","volume":"37","author":"Weber","year":"2019","journal-title":"J Clin Oncol"},{"key":"R28-20250528","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R29-20250528","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab.","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R30-20250528","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1158\/1078-0432.CCR-12-3243","article-title":"Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma.","volume":"19","author":"Feng","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R31-20250528","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage iii melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial.","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000748","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:43:13Z","timestamp":1748468593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CMR.0000000000000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0000000000000748","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}